Ultrasound developer Biosound Esaote reported last month that it has brokered a partnership with Summit Medical Technologies of Arlington Heights, IL. The deal gives Summit exclusive U.S. marketing rights to Indianapolis-based Biosound's Advanced
Ultrasound developer Biosound Esaote reported last month that it has brokered a partnership with Summit Medical Technologies of Arlington Heights, IL. The deal gives Summit exclusive U.S. marketing rights to Indianapolis-based Biosound's Advanced Ultrasonography (AU) line of scanners. Summit will sell the units to radiologists, medical imaging centers, and breast imaging centers, while Biosound's sales force will continue to sell the system to remaining markets, including cardiology, vascular and general surgery, and neurology.
The most recent system in the AU family is AU5, introduced last year and cleared by the Food and Drug Administration this September (SCAN 9/17/97). Biosound hopes the deal with Summit Medical will give it increased access to the multispecialty radiology market and the women's health market.
Study: AI Boosts Ultrasound AUC for Predicting Thyroid Malignancy Risk by 34 Percent Over TI-RADS
February 17th 2025In a study involving assessment of over 1,000 thyroid nodules, researchers found the machine learning model led to substantial increases in sensitivity and specificity for estimating the risk of thyroid malignancy over traditional TI-RADS and guidelines from the American Thyroid Association.
Can CT-Based AI Provide Automated Detection of Colorectal Cancer?
February 14th 2025For the assessment of contrast-enhanced abdominopelvic CT exams, an artificial intelligence model demonstrated equivalent or better sensitivity than radiologist readers, and greater than 90 percent specificity for the diagnosis of colorectal cancer.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.